Deletion of 3p is one of the most frequent genetic alterations in many tumors, including esophageal squamous cell carcinoma (ESCC). In our recent study, deletion of 3p24 was frequently detected in ESCC and one candidate tumor suppressor gene (TSG), p300/CBP-associated factor (PCAF), was identified within the region. In this study, downregulation of PCAF was detected in 23/40 (57.5%) of primary ESCCs and 4/9 (44.4%) of the ESCC cell lines. A further study found that downregulation of PCAF was also associated with hypermethylation of the promoter region of PCAF gene. Methylation-specific PCR found that promoter methylation was detected in 28/40 (70%) of primary ESCCs and 5/9 (55.6%) of ESCC cell lines. In addition, the expression of PCAF could be reactivated in ESCC cell line KYSE510 after demethylation treatment with 5-azadC. Functional studies showed that PCAF was able to suppress tumorigenicity of ESCC cells both in vitro and in vivo, including foci formation, colony formation in soft agar and tumor formation in nude mice. Molecular study found that the tumor suppressive mechanism of PCAF was associated with its role in cell cycle arrest at the G1/S checkpoint by the downregulation of CDK2 and upregulation of p21 waf1/Cip1 , Smad4, Rb and p27 Kip1 . In conclusion, PCAF might be the target TSG responsible for the 3p24 deletion event, which has an important role in the development and progression of ESCC.
Introduction
Esophageal carcinoma (EC) is the seventh most common cancer in the world and the fourth most common cancer in China. As the most common type of EC, esophageal squamous cell carcinoma (ESCC) shows high mortality and regional variation in incidence (Offner, 2000) . Despite advances in multimodality therapy, the prognosis of ESCC remains poor and the overall 5-year survival is less than 15% (Jemal et al., 2005) . Like many of the other solid tumors, the development of ESCC is also believed to be a multistep process caused by the accumulation of the abnormal expression of oncogenes and tumor suppressor genes (TSGs). To date, the exact cellular and molecular mechanisms leading to ESCC have not been systematically evaluated.
Deletion of 3p is one of the most common genetic alterations in ESCC detected by comparative genomic hybridization and loss of heterozygosity (LOH) (Ogasawara et al., 1995; Pack et al., 1999; Yen et al., 2001; Kwong et al., 2004) . In our recent study, the single-nucleotide polymorphism-mass array approach was applied to investigate LOH at 3pter-p14.1 in 100 primary ESCC cases with 350 single-nucleotide polymorphism markers. Four commonly deleted regions at 3p, including 3p24, were detected (Qin et al., 2008) . One candidate TSG, p300/CBP-associated factor (PCAF), at 3p24 was further characterized in this study. PCAF gene is composed of 18 exons and encodes a protein of 832 amino acids. PCAF protein is a histone acetyltransferase that regulates gene transcription through interaction with p300/CBP. PCAF can acetylate histones H3 and H4 to facilitate the downstream gene transcription (Ogryzko et al., 1998) . In addition, PCAF was found to acetylate some other proteins, such as transcription coactivators, to promote their abilities (Schiltz and Nakatani, 2000) . Although the regulation mechanisms of PCAF with E1A, p73 and p53 were widely studied, its role in ESCC development is still unclear (Yang et al., 1996; Zhao et al., 2003) .
In this study, PCAF expression pattern in primary ESCCs and ESCC cell lines was investigated. Downregulation of PCAF was frequently detected, which was caused by either allele loss or promoter methylation or both. As the methylation of promoter region is an early event, identification of methylation-silencing TSGs might be helpful in therapeutic decisions for ESCC patients. The tumor suppressive function of PCAF in ESCC was also studied using both in vitro and in vivo assays. Our findings show that PCAF has an important suppressing role in ESCC development.
Results

Downregulation of PCAF is frequently detected in ESCCs
Expression of PCAF was studied by semiquantitative reverse transcription PCR (RT-PCR) in 40 primary ESCCs and 9 ESCC cell lines. Compared with their paired non-tumorous esophageal tissues, downregulation of PCAF was detected in 23/40 (57.5%) of ESCCs ( Figure 1a ) and 4/9 (44.4%) of ESCC cell lines (Figure 1b ). PCAF expression at protein level was also studied by immunohistochemistry (IHC) staining using ESCC tissue microarray (TMA) containing 221 ESCC cases. Expression of PCAF was detected in 33/36 (91.7%) of informative normal esophageal epithelia. However, an absent expression of PCAF was detected in 62/205 (30.2%) of informative ESCC cases ( Figure 1c ).
The correlation between the downregulation of PCAF and the clinical features of ESCC (Supplementary  Table 1 ) was also studied and the results showed that no significant association was found (Supplementary  Table 2 ).
We noted that the frequency of PCAF expression detected by RT-PCR was lower compared with that detected by IHC, which might be associated with the different evaluation criteria used in the two assays. For RT-PCR, the expression levels of PCAF could be compared between tumor and their paired non-tumorous tissues, and 'downregulation' was used to describe PCAF status in tumor tissues. As no paired nontumorous tissues were available as controls, the expression level of PCAF could not be compared between tumor and their paired non-tumorous tissues in IHC assay. So, 'absent expression' was used to describe PCAF status in tumor tissues, which was much lower in frequency (30.2%) than that detected by RT-PCR assay (57.5%).
Downregulation of PCAF is associated with allele deletion and promoter methylation As a putative mechanism for the downregulation of PCAF in ESCCs, the methylation status of PCAF promoter region was studied. Methylation of a candidate CpG-rich promoter region was studied by methylation-specific PCR in 40 primary ESCCs mentioned above and the results showed that promoter methylation was detected in 28/40 (70%) of ESCCs and 3/40 (7.5%) of the paired non-tumorous tissues, respectively ( Figure 2a) . A further study found that promoter methylation was detected in 19/21 of ESCCs with downregulation of PCAF and 2/21 of ESCCs with the normal expression of PCAF, respectively. Statistical analysis showed that promoter methylation was significantly associated with the downregulation of PCAF (Po0.001). Two ESCC cases with both LOH and methylation showed PCAF expression, which might be caused by the contamination of normal cells in tumor tissue or because of the heterogeneous nature of tumor cells.
Promoter methylation was detected in 6/9 of the ESCC cell lines, including three cell lines (HKESC1, KYSE30 and KYSE510) without PCAF expression (Figure 2b ). To further study the correlation of downregulation of PCAF with DNA copy loss and promoter methylation, fluorescence in situ hybridization and methylation-specific PCR were used to test whether the absent expression of PCAF in KYSE510 cells was caused by the inactivation of both PCAF alleles. The fluorescence in situ hybridization result showed that KYSE510 contains one intact chromosome 3 and two PCAF-deleted chromosome 3 (Figure 2c ). Interestingly, the promoter region of the remaining PCAF allele in KYSE510 cells was methylated (Figure 2b ). When KYSE510 cells were treated with 5-aza-dC, the expression of PCAF could be reactivated (Figure 2d ), indicating that both promoter methylation and DNA copy loss contributed to the absent expression of PCAF gene. In our previous study, the loss of one PCAF allele has been detected in 14/40 (35%) of ESCC specimens by single-nucleotide polymorphism array (Qin et al., 2008) . In these cases, the downregulation of PCAF was detected in 23 (57.5%) of the specimens. In 23 cases with downregulation of PCAF, inactivation of PCAF in 22 (95.7%) cases was correlated with either LOH (n ¼ 2) or methylation (n ¼ 13) only, or both LOH and methylation (n ¼ 7, Figure 2e and Supplementary Table  3 ). Statistical analysis showed that the downregulation of PCAF was significantly associated with allele loss and promoter methylation (Po0.05, Fisher's exact test).
PCAF suppresses tumorigenicity in ESCC cells
To study the tumor suppressive function of PCAF, PCAF was stably transfected into KYSE510 cells. Empty vector-transfected KYSE510 cell (Vec-510) was used as control. PCAF expression was confirmed by . Compared with Vec-510 cells, in vitro tumor suppressive assays showed that introducing PCAF gene into KYSE510 cells could inhibit their tumorigenic ability, including a significant decrease in colony formation in soft agar (Po0.001, Figure 3b ), decrease in foci formation frequency (Po0.001, Figure 3c ) and inhibition of cell growth rate in PCAF-510 cells (Po0.001, Figure 3d ).
PCAF inhibits tumorigenicity of ESCC in nude mice
To further explore the in vivo tumor suppressive ability of PCAF, tumor formation in nude mice was examined with PCAF-510 cells. PCAF-510 and Vec-510 cells were injected subcutaneously into the left and right hind legs of 10 nude mice, respectively. Within 2 weeks, solid tumors were readily visible in all 10 tested mice injected with Vec-510 cells (right hind leg), but no visible tumor was found in any tested mice injected with PCAF-510 cells (left hind leg). Although a visible tumor could be found on both hind legs at 4 weeks, the tumor size induced by PCAF-510 cells (tumor volume: 6.5±0.6 mm 3 ) was significantly smaller than the tumor size (49.5 ± 4.0 mm 3 ) induced by Vec-510 cells (Po0.001, Figure 3e ). These results showed that PCAF has a strong tumor suppressive ability both in vitro and in vivo.
PCAF is able to arrest cell cycle at G1/S phase To elucidate the mechanism underlying growth inhibition by PCAF, the cell cycle distributions of PCAF-510 and Vec-510 cells were compared by flow cytometry. PCAF-510 showed an accumulation of cells in G0/G1 phases and a decrease in S-phase cells compared with Vec-510 (Figure 4a ), suggesting that PCAF is able to inhibit DNA synthesis and G1/S-phase transition. To investigate the potential molecular mechanism of PCAF in cell cycle arrest, we examined the effects of PCAF on several key cell cycle regulators, including p21 waf/cip1 , p27 kip1 , p53, Rb, Cyclin D1, CDK2 and Smad4. Increased expressions of Smad4, p21, p27, Rb, p53 and Cyclin D1, and a decreased expression of CDK2 were detected in PCAF-510 cells, compared with those in Vec-510 cells (Figure 4b) .
Two mutations of p53 in KYSE510, a deletion at codon 241 and a point mutation at codon 343 (GAG to TAG), have been reported (Tanaka et al., 1996; Forbes et al., 2006) . To confirm if KYSE510 contains a wildtype p53, sequencing analysis of p53 gene was performed. Eight clones were sequenced and no deletion at codon 241 was detected. Wild-type and mutant codon 343 was detected in 3/8 and 5/8 of clones, respectively. These data suggest that KYSE510 still contains wildtype p53.
PCAF cannot induce apoptosis
To test if PCAF has a role in inducing apoptosis, the apoptotic index between PCAF-510 and Vec-510 cells was compared by terminal deoxynucleotidyl transferase dUTP nick-end labeling assay. The result showed that no obvious difference was detected in the apoptotic index between PCAF-510 and Vec-510 cells (Figure 5a ). In addition, the apoptotic index between PCAF-510 and Vec-510 cells was also compared after staurosporine treatment and no obvious difference was found (Figure 5a ). These data indicated that the tumor suppressive effect of PCAF was not through inducing apoptosis in ESCC.
PCAF upregulates other tumor suppressors in PCAF-transfected tumors As shown in Figure 4b , PCAF is able to arrest cell cycle at G1/S checkpoint through upregulating tumor suppressors including p21 , p27 kip1 , p53, Rb, Smad4 and Cyclin D1 were upregulated, whereas the expression of CDK2 was downregulated. These results are consistent with those detected in PCAF-transfected KYSE510 cells (Figure 5b and c) .
Discussion
Deletion of 3p is one of the most frequent chromosomal changes in many malignancies including ESCC. Several candidate TSGs at 3p have been reported, including FHIT at 3p14.2, RASSF1A at 3p21.3 and VHL at 3p25-26 (Kuroki et al., 2003) . The genetic abnormalities of these genes at 3p have an important role in the development of lung cancer and renal cancer. In our recent study, we provided the first evidence that 3p24 was one of the most frequently deleted regions in ESCC and PCAF was identified as a candidate TSG (Qin et al., 2008) . In this study, we found that mRNA expression of PCAF was absent in 44.4% of ESCC cell lines and 57.5% of primary ESCC tumors. TMA study showed that the absent expression of PCAF at protein level was detected in 30.2% of primary ESCCs. These results indicated that downregulation of PCAF may have an important role in the development of ESCC.
In addition to deletion of TSGs, epigenetic change is another major mechanism for the inactivation of TSG in cancer cells. In this study, methylation of the promoter region of PCAF was frequently detected in ESCCs and ESCC cell lines, which might be a possible mechanism to decrease PCAF expression in ESCC. In ESCC cell line KYSE510, loss of two copies of PCAF alleles and promoter methylation of the remaining PCAF allele are responsible for the absent expression of PCAF. These findings indicated the 'two-hit' inactivation of PCAF gene in ESCC, similar to that of other TSGs such as PLCD1 reported previously (Fu et al., 2007) .
The tumor suppressive function of PCAF by both in vitro and in vivo assays further supports its role as a TSG in the development of ESCC. The results showed that PCAF could effectively suppress cell growth, decrease foci formation and colony formation in soft agar, and inhibit tumor formation in nude mice. A further study revealed that PCAF was able to inhibit G1/S-phase transition through the downregulation of CDK2 and the upregulation of p53, p21 waf1/cip1 , Smad4, Rb, p27 kip1 and Cyclin D1. p21 Waf1/Cip1 and p27
Kip1
, downstream transcriptional targets of p53, serve as key mediators in G1/S transition through Cdk inhibition and regulate the activity of CDK2 complex, which are essential for S phase entry (Carnero and Hannon, 1998) . The upregulation of p21
Waf1/Cip1 and p27 Kip1 caused by PCAF facilitates the inactivation of CDK2, resulting in CDK2-medicated Rb expression and enhanced Rb-E2F binding (Harbour et al., 1999; Vogelstein et al., 2000) . The latter event is a key point control from G1-to S-phase transition in cycling epithelial cells (Chan et al., 2001) . Smad4 belongs to the evolutionarily conserved family of Smad proteins that are crucial mediators of signals from the transforming growth factor superfamily of cytokines. The overexpression of Smad4 can bypass transforming growth factor-b receptor activation and induce the expression of p21 Waf1/Cip1 , the downstream target gene of Smad4 (Chiao et al., 1999) . One study found that PCAF is not only a coactivator of p53, participating in p53 transactivation of target genes through histone acetylation, but also one of the target genes upregulated by p53 (Watts et al., 2004) . These findings indicate that PCAF might be necessary for orderly G1/S transition in ESCC cells. One unexpected finding is that PCAF could upregulate the expression of Cyclin D1. Cyclin D1 could be upregulated by pRb in breast cancer (de Jong et al., 1998) and be compensated by the upregulation of p21
Waf1/Cip1 in human myeloid leukemia cells (Ullmannova et al., 2003) . Therefore, the overexpression of Cyclin D1 may not necessarily be associated with the high proliferation of cells (Atadja et al., 1995) .
PCAF was initially identified as a histone acetylase. Further studies found that its substrates are not limited to histones, but also include other cellular factors involved in transcriptional regulation (Schiltz and Nakatani, 2000) . PCAF and p300/CBP can form a multiprotein complex that has an important role in the regulation of many growth suppressive genes, such as E1A, Rb, p53 and p16
INK4a (Martinez-Balbas et al., 2000; Wang et al., 2008) . Similar to PCAF, an aberrant methylation of the promoter region of p300 was also frequently detected in ESCC (Zhang et al., 2007) , suggesting that the hypermethylation of promoter regions of PCAF and p300/CBP genes is one of the mechanisms involved in the inactivation of these genes.
In summary, in this study we provided evidences that PCAF is a TSG, including the following facts: (1) PCAF is frequently downregulated in ESCC specimens compared with their paired non-tumorous tissues; (2) the downregulation of PCAF is associated with its allele loss and/or promoter methylation; (3) the introduction of PCAF into ESCC cells could inhibit cell growth rate, cell proliferation, colony formation in soft agar and tumor formation in nude mice; (4) the ectopic expression of PCAF is able to arrest cell cycle at G1/S checkpoint by upregulating p53, p21 waf1/cip1 , smad4, Rb and p27 kip1 and downregulating CDK2. A better understanding of the tumor suppressive role of PCAF will significantly improve our knowledge in the development of ESCC, and may lead to a more effective management of ESCC with the inactivation of PCAF.
Materials and methods
Cell lines and primary ESCC specimens
Chinese ESCC cell line HKESC1 was kindly provided by Professor Srivastava (Department of Pathology, The University of Hong Kong, Hong Kong, China), and two immortalized esophageal cell lines (NE1 and NE3) and two Chinese ESCC cell lines (EC18 and EC109) were kindly provided by Professor Tsao (Department of Anatomy, The University of Hong Kong). Six Japanese ESCC cell lines (KYSE30, KYSE140, KYSE180, KYSE410, KYSE510 and KYSE520) (Shimada et al., 1992) were obtained from DSMZ (Braunschweig, Germany), the German Resource Centre for Biological Material. Forty pairs of primary ESCC and nontumorous tissues were collected immediately after surgical resection at Linzhou Cancer Hospital (Henan, China). Samples used in this study were approved by the Committees for Ethical Review of Research involving Human Subjects at Zhengzhou University and the University of Hong Kong.
Semiquantitative RT-PCR Total RNA was extracted from cell lines, frozen PCAF-or empty vector-transfected tumors, and frozen ESCC tissues using TRIzol Reagent kit (Invitrogen, Carlsbad, CA, USA). Reverse transcription of total RNA (2 mg) was performed using an Advantage RT for PCR Kit (Clontech, Mountain View, CA, USA), and cDNA was subjected to PCR for a 30-cycle amplification with primers for PCAF, p21, p27, p73, Rb, Smad4 and Cyclin D1. GAPDH and 18s were used as internal control.
Methylation analysis of promoter region of PCAF Genomic DNA was treated by bisulfite and then studied by methylation-specific PCR as previously described (Fu et al., 2007) . Methylation-specific PCR primers were M1: 5 0 -TTTTT TAGCGTTGGTAGATATC, M2: 5 0 -GCTAATAATAATAA CGACGACG, and unmethylation-specific primers were U1: 5 0 -GTTTTTTAGTGTTGGTAGATATT and U2: 5 0 -ACACT AAT AATAATAACAACAACA. To study whether demethylation could restore PCAF expression in KYSE510 cells, 2 Â 10 5 cells were treated with 50 mM 5-aza-dC (Sigma-Aldrich Corporation, St Louis, MO, USA) for 3 days, with 5-Aza-dC and the medium changing every 24 h. Total RNA was then extracted and PCAF expression was determined by RT-PCR.
Fluorescent in situ hybridization A bacterial artificial chromosome clone containing PCAF gene (RP11-1076P5) was used to study DNA copy number change in KYSE510 cells. Bacterial artificial chromosome clone and chromosome 3 centromere probe were labeled with Spectrum Orange-dUTP and Spectrum Green-dUTP (Vysis), respectively. Fluorescence in situ hybridization reaction was performed as described previously (Guan et al., 2001) .
TMAs and IHC
A total of 221 formalin-fixed and paraffin-embedded ESCC tumor specimens used for TMA construction were obtained from the archives of Cancer Center, Sun Yat-Sen University (Guangzhou, China Colony formation in soft agar was performed by growing 4 Â 10 3 cells in 0.4% bactoagar on a bottom layer of solidified 0.6% bactoagar in six-well plates. After 3 weeks, colonies consisting of more than 80 cells were counted and represented as the means ± s.d. of triplicate within the same experiment. Cell growth rate of PCAF-510 and Vec-510 cells was compared by the MTT assay. Cells were plated onto 96-well culture plate at a density of 8 Â 10 2 cells per well. The cell growth rate was detected using cell proliferation MTT kit (Sigma) according to the manufacturer's instruction. The experiments were performed in triplicate.
Tumor formation in nude mice in vivo tumor suppressive ability of PCAF was investigated by tumor xenograft experiment. PCAF-510 and control Vec-510 cells (2 Â 10 6 cells in a volume of 200 ml) were injected subcutaneously into the left and right hind legs of 10 nude mice (4-6 weeks old), respectively. Tumor formation on nude mice was monitored over a 3-week period. The tumor volume was calculated by the formula V ¼ 0.5 Â L Â W 2 (Cao et al., 2002) .
Flow cytometric analysis PCAF-510 or Vec-510 cells (1-2 Â 10 6 ) were fixed in 70% ethanol, stained with propidium iodide and DNA content was analysed by Cytomics FC (Beckman Coulter, Fullerton, CA, USA). Finally, the cell cycle profiles were analysed with Modfit LT 2.0.
Terminal deoxynucleotidyl transferase dUTP nick-end labeling assay PCAF-510 and Vec-510 cells were seeded onto coverslips in a six-well plate overnight and then treated with 1 mM staurosporine for 3 h. Cells will be fixed with 4% paraformaldehyde and incubated with the terminal deoxynucleotidyl transferase dUTP nick-end labeling reaction mixture for 60 min at 37 1C. Apoptotic cells will be determined with In Situ Cell Death Detection Kit, POD (Roche, Mannheim, Germany), which quantitatively determines DNA fragmentation visualized under fluorescent microscope. The percentages of terminal deoxynucleotidyl transferase dUTP nick-end labeling-positive cells were counted and the apoptosis index was calculated. The experiments were performed in triplicate.
Western blot analysis
Quantified protein lysates (10 mg) were resolved on an SDSpolyacrylamide gel electrophoresis gel, transferred onto a polyvinylidene fluoride membrane (Millipore, Billerica, MA, USA) and immunoblotted with antibodies for PCAF, Smad4, Rb, CDK2 and Tublin (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), p21 and p53 (Cell Signaling Technology, Danvers, MA, USA).
p53 mutational analysis Genomic DNA of tested cells was amplified with the following primers: for exon 7-Fw: 5 0 -GGCCTGTGTTATCTCCTAG and Rv: 5 0 -CTCCATCTACTCCCAACCA; for exon 10-Fw: 5 0 -TCAGGTACTGTGAATATACTTACTT and Rv: 5 0 -GGTTTGGATGTTCTGTGGA. Gel-purified PCR products were ligated into TA-sequencing vector (Promega, Madison, WI, USA) and sequenced by SeqMan II (DNAS-TAR Inc., Madison, WI, USA).
Statistical analysis
Statistical analysis was performed with the SPSS standard version 13.0 (SPSS Inc., Chicago, IL, USA). The statistical significance of the correlation was assessed by w 2 -test or the Fisher's exact test. Results expressed as mean ± s.d. were analysed using the Student's t-test. Differences were considered as significant when the P-value was less than 0.05.
